MedTrace Logo

Safety in Convalescent Plasma Transfusion to COVID-19

NCT04333355 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2021-02-10

No results posted yet for this study

Summary

There is currently no specific vaccine or treatment to treat critically ill patients with COVID-19. Different therapies are still under investigation and are use in different health institutions, however, a significant proportion of patients do not respond to these treatments, so it is important to seek new treatments. One of these alternatives is the use of convalescent plasma. The investigator will use plasma obtained from convalescent individuals with proven novel SARS-CoV-2 virus infection, diagnosed with coronavirus-19-induced disease and symptom-free for a period of not less than 10 days since they recovered from the disease. This plasma will be infused in patients affected by the same virus, but who have developed respiratory complications that have not responded favorably to usual treatment such as chloroquine, hydroxychloroquine, azithromycin, and other antivirals. The investigator will evaluate the safety of this procedure by accounting for any adverse event.

Conditions

Interventions

BIOLOGICAL

Convalescent Plasma

Along with the administration of convalescent plasma, patients will continue to receive supportive standard care.

Sponsors & Collaborators

  • Tecnologico de Monterrey

    collaborator OTHER

  • TecSalud Investigación Clínica

    lead OTHER

Principal Investigators

  • José Fe Castilleja-Leal, MD. · Hospital San José

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-08
Primary Completion
2020-08-20
Completion
2020-08-20

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04333355 on ClinicalTrials.gov